Holen Sie sich die Stockscreener-App
4.5844
3.27%
0.1444
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MNKD?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.44
Offen:
$4.49
24-Stunden-Volumen:
566.82K
Relative Volume:
0.28
Marktkapitalisierung:
$1.41B
Einnahmen:
$248.37M
Nettoeinkommen (Verlust:
$11.74M
KGV:
91.69
EPS:
0.05
Netto-Cashflow:
$18.24M
1W Leistung:
-1.19%
1M Leistung:
-12.16%
6M Leistung:
-30.95%
1J Leistung:
+11.56%
1-Tages-Spanne:
$4.48
$4.69
1-Wochen-Bereich:
$4.40
$4.69
52-Wochen-Spanne:
$4.06
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Firmenname
Mannkind Corp
Sektor
Branche
Telefon
818-661-5000
Adresse
1 CASPER STREET, DANBURY, CA
Vergleichen Sie MNKD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.585 | 1.41B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.08 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.23 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.32 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.66 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.34 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-10 | Eingeleitet | Wedbush | Outperform |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-10-10 | Eingeleitet | Wedbush | Outperform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-03-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2018-02-28 | Herabstufung | Maxim Group | Hold → Sell |
| 2017-11-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-10-06 | Bestätigt | Maxim Group | Buy |
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-05-10 | Bestätigt | Piper Jaffray | Underweight |
| 2016-05-10 | Bestätigt | RBC Capital Mkts | Underperform |
| 2016-01-06 | Bestätigt | Piper Jaffray | Underweight |
| 2016-01-06 | Bestätigt | RBC Capital Mkts | Underperform |
| 2015-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Herabstufung | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-05-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Bestätigt | MLV & Co | Hold |
| 2015-04-16 | Bestätigt | RBC Capital Mkts | Outperform |
Alle ansehen
Mannkind Corp Aktie (MNKD) Neueste Nachrichten
Is MannKind Corporation (MNKD) the Best Quality Penny Stock to Buy According to Hedge Funds? (READY TO EDIT2) - Insider Monkey
Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
MannKind Co. (NASDAQ:MNKD) Shares Sold by Prudential Financial Inc. - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Mizuho sets MannKind stock Outperform with $12 target - Investing.com
Mizuho sets MannKind stock Outperform with $12 target By Investing.com - Investing.com India
Diabetes Meets Racing: MannKind's Game-Changing Partnership With Type 1 Diabetic IndyCar Star - Stock Titan
MannKind To Support Conor Daly - speed sport
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options - Yahoo Finance
Cantor maintains Overweight rating on MannKind stock at $9 target - Investing.com
Why It's Worth Keeping An Eye On MannKind - RTTNews
Inhalable Biologics Industry Report 2025: World Market to Nearly Triple in Size by 2030, Reaching $10.06 Billion at a CAGR of 17.6% - Yahoo Finance
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com India
MAC Lung Disease Market Statistics Expected to Experience Major - openPR
MannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025 - Nasdaq
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 - Yahoo Finance
AllPennyStocks.com News: Companies Looking Towards Future Revenue with New Diabetes Therapies - ACCESS Newswire
Commit To Purchase MannKind At $3, Earn 13.3% Using Options - Nasdaq
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Non- Tuberculous Mycobacterial Infections Market on Track - openPR
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ - MSN
MannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
MannKind Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus.com
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question - Seeking Alpha
MannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Call Transcript - Insider Monkey
MannKind: Q4 Earnings Snapshot - mySA
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Re - GuruFocus.com
MannKind Corp Q4 Earnings: EPS Meets Estimates at $0.03, Revenue Surpasses Expectations at $77 Million - GuruFocus.com
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Mannkind stock gains amid Q4 report, business update - MSN
MannKind Corp reports results for the quarter ended December 31Earnings Summary - TradingView
MannKind (MNKD) Q4 Earnings Meet Estimates - Yahoo Finance
Earnings call transcript: MannKind Q4 2024 beats EPS forecast, stock jumps - Investing.com
MannKind earnings beat by $0.05, revenue topped estimates - Investing.com
MannKind shares move 4% higher on strong revenue growth By Investing.com - Investing.com South Africa
MannKind shares move 4% higher on strong revenue growth - Investing.com
MANNKIND CORP SEC 10-K Report - TradingView
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
MannKind Corp (MNKD) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Exploring Three High Growth Tech Stocks in the United States - Yahoo Finance
MannKind: Q2 Earnings Snapshot -August 07, 2024 at 08:09 am EDT - Marketscreener.com
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 - Yahoo Finance
MannKind Sets Stage for 2024 Performance Review: CEO and CFO to Unveil Full Year Results - Stock Titan
MannKind (MNKD) Expected to Announce Earnings on Tuesday - MarketBeat
Wedbush Initiates Coverage on MannKind (NASDAQ:MNKD) - MarketBeat
MannKind To Present At Oppenheimer Healthcare Life Sciences Conference; Webcast At 11:20 AM ET - Nasdaq
An Analysis of Mannkind Corp (MNKD)’s Potential Price Growth - Knox Daily
Finanzdaten der Mannkind Corp-Aktie (MNKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mannkind Corp-Aktie (MNKD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Binder Steven B. | Director |
Nov 22 '24 |
Sale |
6.89 |
67,536 |
465,323 |
1,075,026 |
1.75%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):